A new report by the Public Accounts Committee found that the UK Test and Trace strategy, costing roughly £37 billion over two years, failed to ever meet 24 hour test result deadlines.
According to new data, COVID care home deaths in the United States are influenced by race - with majority non-White care homes experiencing 3.3 times more deaths.
A new medical education programme for diabetes healthcare providers in the UK is focusing on upskilling the knowledge and training of diabetes management technologies & devices.
Arun Swaminathan MD, Assistant Professor of Neurology and Epilepsy at the University of Nebraska Medical Center, considers the importance of improving infrastructure and management of epilepsy research.
Researchers at Yale believe that blood tests could predict severe or critical COVID cases, because blood holds a series of interesting biological signals about a person.
The UK has found six confirmed cases of the Brazilian COVID mutation yesterday (28 February) - but an individual who tested positive three weeks ago is still being traced throughout the country.
New data suggests that before 60 days of COVID symptoms beginning is the best window for convalescent plasma donation - which is how antibodies were created in countless COVID-19 patients before vaccines.
The Government unveiled the confirmed priority groups for phase two of UK vaccinations - the Joint Committee on Vaccination and Immunisation (JCVI) is choosing age as the deciding factor.
Germans have only taken 270,986 AstraZeneca doses so far, leaving roughly 1.17 million doses in storage across the country - but these shots are due to expire in less than six months.
Cecilia Van Cauwenberghe from Frost & Sullivan’s TechCasting Group, explains how the COVID-19 pandemic is the scenario for testing and demonstrating the successful implementation of diabetes telehealth platforms.
New documents from the FDA show that the Johnson & Johnson vaccine appears to be 86% effective against COVID-19 - signalling that it will soon be approved in the US.
Michael Morrison, Senior Researcher in Social Science at the University of Oxford, illustrates the importance of emerging biomedical innovations in the UK.
The research team believe that some people have a genetic predisposition that increases likelihood of severe COVID, which may be crucial to understanding how mutations could change outcomes.